» Articles » PMID: 27211995

The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment

Overview
Specialty Psychiatry
Date 2016 May 24
PMID 27211995
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid agonist therapies (OAT) to treat opioid addiction in people who inject drugs (PWID) began in Ukraine in 2004. Scale-up of OAT, however, has been hampered by both low enrollment and high attrition. To better understand the factors influencing OAT retention among PWID in Ukraine, qualitative data from 199 PWIDs were collected during 25 focus groups conducted in five Ukrainian cities from February to April 2013. The experiences of PWID who were currently or previously on OAT or currently trying to access OAT were analyzed to identify entry and retention barriers encountered. Transcribed data were analyzed using a grounded theory approach. Individual beliefs about OAT, particularly misaligned treatment goals between clients and providers, influenced PWID's treatment seeking behaviors. Multiple programmatic and structural issues, including inconvenient hours and treatment site locations, complicated dosing regimens, inflexible medication dispensing guidelines, and mistreatment by clinic and medical staff also strongly influenced OAT retention. Findings suggest the need for both programmatic and policy-level structural changes such as revising legal regulations covering OAT dispensing, formalizing prescription dosing policies and making OAT more available through other sites, including primary care settings as a way to improve treatment retention. Quality improvement interventions that target treatment settings could also be deployed to overcome healthcare delivery barriers. Additional patient education and medical professional development around establishing realistic treatment goals as well as community awareness campaigns that address the myths and fears associated with OAT can be leveraged to overcome individual, family and community-level barriers.

Citing Articles

Decrease in provider stigma is associated with improved quality health indicators among individuals receiving methadone in primary care centers in Ukraine.

Machavariani E, Bromberg D, Dumchev K, Esserman D, Earnshaw V, Pykalo I Int J Drug Policy. 2024; 136:104682.

PMID: 39705875 PMC: 11821433. DOI: 10.1016/j.drugpo.2024.104682.


Disruptions to HIV Prevention During Armed Conflict in Ukraine and Other Settings.

Nikitin B, Bromberg D, Ivasiy R, Madden L, Machavariani E, Dvoriak S Curr HIV/AIDS Rep. 2024; 22(1):10.

PMID: 39672977 PMC: 11823171. DOI: 10.1007/s11904-024-00716-x.


A qualitative dyad analysis of barriers and facilitators of antiretroviral therapy (ART) adherence among people who inject drugs (PWID) with HIV in Kazakhstan.

Neuenschwander P, Altice F, Remien R, Mergenova G, Sarsembayeva L, Rozental E AIDS Care. 2024; 37(1):151-160.

PMID: 39404196 PMC: 11682916. DOI: 10.1080/09540121.2024.2414078.


Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine.

Machavariani E, Dumchev K, Pykalo I, Filippovych M, Ivasiy R, Esserman D Contemp Clin Trials. 2024; 146:107690.

PMID: 39265780 PMC: 11531372. DOI: 10.1016/j.cct.2024.107690.


"If they get out of drug rehab centers, they're on their own": Opportunities and challenges for people released from compulsory drug rehabilitation centers to communities in Vietnam.

Giang L, Trang N, Hoe H, Anh N, Thuy D, Bart G Int J Drug Policy. 2024; 128:104443.

PMID: 38743963 PMC: 11213659. DOI: 10.1016/j.drugpo.2024.104443.


References
1.
Strike C, Gnam W, Urbanoski K, Fischer B, Marsh D, Millson M . Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addict Behav. 2005; 30(5):1025-8. DOI: 10.1016/j.addbeh.2004.09.004. View

2.
Strain E, Bigelow G, Liebson I, Stitzer M . Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999; 281(11):1000-5. DOI: 10.1001/jama.281.11.1000. View

3.
Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B . Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008; 103(9):1484-92. DOI: 10.1111/j.1360-0443.2008.02249.x. View

4.
Brewin C, Bradley C . Patient preferences and randomised clinical trials. BMJ. 1989; 299(6694):313-5. PMC: 1837157. DOI: 10.1136/bmj.299.6694.313. View

5.
Haddad M, Zelenev A, Altice F . Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013; 131(1-2):127-35. PMC: 3674170. DOI: 10.1016/j.drugalcdep.2012.12.008. View